Screener
SELLAS Life Sciences Group, Inc. SLS Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by SELLAS Life Sciences Group, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:01 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001390478-26-000008
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 6,765 | 7,474 |
| Commitments and contingencies (Note 5) | ||
| Stockholders’ equity: | ||
| Common stock, $0.0001 par value; 350,000,000 shares authorized, 181,332,574 and 153,103,459 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 18 | 15 |
| Additional paid-in capital | 390,789 | 345,844 |
| Accumulated deficit | (283,395) | (274,988) |
| Total stockholders’ equity | 107,412 | 70,871 |
| Total liabilities and stockholders’ equity | $114,177 | $78,345 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is SELLAS Life Sciences Group, Inc.'s total equity?
- SELLAS Life Sciences Group, Inc. (SLS) reported total equity of $107.41M in Q1 2026.
- How has SELLAS Life Sciences Group, Inc.'s total equity changed year-over-year?
- SELLAS Life Sciences Group, Inc.'s total equity increased by 286.9% year-over-year, from $27.76M to $107.41M.
- What is the long-term trend for SELLAS Life Sciences Group, Inc.'s total equity?
- Over 5 years (2020 to 2025), SELLAS Life Sciences Group, Inc.'s total equity has grown at a 20.4% compound annual growth rate (CAGR), from $27.96M to $70.87M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about SELLAS Life Sciences Group, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude